ACB
Price
$4.29
Change
-$0.10 (-2.27%)
Updated
Mar 13, 04:59 PM (EDT)
Capitalization
238.86M
97 days until earnings call
CYTH
Price
$0.73
Change
+$0.06 (+8.96%)
Updated
Mar 13, 04:54 PM (EDT)
Capitalization
39.05M
3 days until earnings call
Ad is loading...

ACB vs CYTH

Header iconACB vs CYTH Comparison
Open Charts ACB vs CYTHBanner chart's image
Aurora Cannabis
Price$4.29
Change-$0.10 (-2.27%)
Volume$3.61K
Capitalization238.86M
Cyclo Therapeutics
Price$0.73
Change+$0.06 (+8.96%)
Volume$100
Capitalization39.05M
ACB vs CYTH Comparison Chart
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. CYTH commentary
Mar 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and CYTH is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Mar 14, 2025
Stock price -- (ACB: $4.40 vs. CYTH: $0.67)
Brand notoriety: ACB: Notable vs. CYTH: Not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ACB: 20% vs. CYTH: 1%
Market capitalization -- ACB: $238.86M vs. CYTH: $39.05M
ACB [@Pharmaceuticals: Other] is valued at $238.86M. CYTH’s [@Pharmaceuticals: Other] market capitalization is $39.05M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileCYTH’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • CYTH’s FA Score: 0 green, 5 red.
According to our system of comparison, ACB is a better buy in the long-term than CYTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 2 TA indicator(s) are bullish while CYTH’s TA Score has 2 bullish TA indicator(s).

  • ACB’s TA Score: 2 bullish, 7 bearish.
  • CYTH’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, ACB is a better buy in the short-term than CYTH.

Price Growth

ACB (@Pharmaceuticals: Other) experienced а -12.52% price change this week, while CYTH (@Pharmaceuticals: Other) price change was -5.50% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.08%. For the same industry, the average monthly price growth was -2.21%, and the average quarterly price growth was -1.37%.

Reported Earning Dates

ACB is expected to report earnings on Jun 19, 2025.

CYTH is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-0.08% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($239M) has a higher market cap than CYTH($39.1M). CYTH YTD gains are higher at: 14.169 vs. ACB (3.529). CYTH has higher annual earnings (EBITDA): -20.03M vs. ACB (-1.64B). ACB has more cash in the bank: 149M vs. CYTH (9.25M). CYTH has less debt than ACB: CYTH (1.03M) vs ACB (103M). ACB has higher revenues than CYTH: ACB (212M) vs CYTH (1.08M).
ACBCYTHACB / CYTH
Capitalization239M39.1M611%
EBITDA-1.64B-20.03M8,173%
Gain YTD3.52914.16925%
P/E RatioN/AN/A-
Revenue212M1.08M19,703%
Total Cash149M9.25M1,611%
Total Debt103M1.03M9,971%
FUNDAMENTALS RATINGS
ACB vs CYTH: Fundamental Ratings
ACB
CYTH
OUTLOOK RATING
1..100
6651
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6264
P/E GROWTH RATING
1..100
81100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACB's Valuation (57) in the Pharmaceuticals Other industry is in the same range as CYTH (87) in the null industry. This means that ACB’s stock grew similarly to CYTH’s over the last 12 months.

ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as CYTH (100) in the null industry. This means that ACB’s stock grew similarly to CYTH’s over the last 12 months.

ACB's SMR Rating (100) in the Pharmaceuticals Other industry is in the same range as CYTH (100) in the null industry. This means that ACB’s stock grew similarly to CYTH’s over the last 12 months.

ACB's Price Growth Rating (62) in the Pharmaceuticals Other industry is in the same range as CYTH (64) in the null industry. This means that ACB’s stock grew similarly to CYTH’s over the last 12 months.

ACB's P/E Growth Rating (81) in the Pharmaceuticals Other industry is in the same range as CYTH (100) in the null industry. This means that ACB’s stock grew similarly to CYTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBCYTH
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 21 days ago
77%
Bullish Trend 7 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MMI34.950.27
+0.78%
Marcus & Millichap
HBCP43.82-0.14
-0.32%
Home Bancorp
FSK21.64-0.10
-0.46%
FS KKR Capital Corp
HLT228.40-3.43
-1.48%
Hilton Worldwide Holdings
BNED8.57-0.17
-1.95%
Barnes & Noble Education

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been closely correlated with CGC. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
+1.62%
CGC - ACB
82%
Closely correlated
+1.82%
TLRY - ACB
73%
Closely correlated
+4.92%
CRON - ACB
67%
Closely correlated
-0.53%
SNDL - ACB
65%
Loosely correlated
+1.99%
OGI - ACB
61%
Loosely correlated
+3.10%
More

CYTH and

Correlation & Price change

A.I.dvisor tells us that CYTH and ACB have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYTH and ACB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTH
1D Price
Change %
CYTH100%
-0.50%
ACB - CYTH
24%
Poorly correlated
+1.62%
RDHL - CYTH
24%
Poorly correlated
+1.61%
TEVA - CYTH
22%
Poorly correlated
+2.36%
CGC - CYTH
22%
Poorly correlated
+1.82%
PTPI - CYTH
21%
Poorly correlated
-10.34%
More